Literature DB >> 14694197

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.

Eric Prieur1, Sarah C Gilbert, Joerg Schneider, Anne C Moore, Eric G Sheu, Nilu Goonetilleke, Kathryn J H Robson, Adrian V S Hill.   

Abstract

To generate broadly protective T cell responses more similar to those acquired after vaccination with radiation-attenuated Plasmodium falciparum sporozoites, we have constructed candidate subunit malaria vaccines expressing six preerythrocytic antigens linked together to produce a 3240-aa-long polyprotein (L3SEPTL). This polyprotein was expressed by a plasmid DNA vaccine vector (DNA) and by two attenuated poxvirus vectors, modified vaccinia virus Ankara (MVA) and fowlpox virus of the FP9 strain. MVAL3SEPTL boosted anti-thrombospondin-related adhesive protein (anti-TRAP) and anti-liver stage antigen 1 (anti-LSA1) CD8(+) T cell responses when primed by single antigen TRAP- or LSA1-expressing DNAs, respectively, but not by DNA-L3SEPTL. However, prime boost regimes involving two heterologous viral vectors expressing L3SEPTL induced a strong cellular response directed against an LSA1 peptide located in the C-terminal region of the polyprotein. Peptide-specific T cells secreted IFN-gamma and were cytotoxic. IFN-gamma-secreting T cells specific for each of the six antigens were induced after vaccination with L3SEPTL, supporting the use of polyprotein inserts to induce multispecific T cells against P. falciparum. The use of polyprotein constructs in nonreplicating poxviruses should broaden the target antigen range of vaccine-induced immunity and increase the number of potential epitopes available for immunogenetically diverse human populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14694197      PMCID: PMC314178          DOI: 10.1073/pnas.0307158101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites.

Authors:  I I Moelans; J F Meis; C Kocken; R N Konings; J G Schoenmakers
Journal:  Mol Biochem Parasitol       Date:  1991-04       Impact factor: 1.759

2.  Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants.

Authors:  D A Fidock; H Gras-Masse; J P Lepers; K Brahimi; L Benmohamed; S Mellouk; C Guerin-Marchand; A Londono; L Raharimalala; J F Meis
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

3.  Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast.

Authors:  I I Moelans; J Cohen; M Marchand; C Molitor; P de Wilde; J F van Pelt; M R Hollingdale; W F Roeffen; W M Eling; C T Atkinson
Journal:  Mol Biochem Parasitol       Date:  1995-06       Impact factor: 1.759

Review 4.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP.

Authors:  D A Fidock; E Bottius; K Brahimi; I I Moelans; M Aikawa; R N Konings; U Certa; P Olafsson; T Kaidoh; A Asavanich
Journal:  Mol Biochem Parasitol       Date:  1994-04       Impact factor: 1.759

6.  A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite.

Authors:  K J Robson; J R Hall; M W Jennings; T J Harris; K Marsh; C I Newbold; V E Tate; D J Weatherall
Journal:  Nature       Date:  1988-09-01       Impact factor: 49.962

7.  A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning.

Authors:  C Guerin-Marchand; P Druilhe; B Galey; A Londono; J Patarapotikul; R L Beaudoin; C Dubeaux; A Tartar; O Mercereau-Puijalon; G Langsley
Journal:  Nature       Date:  1987 Sep 10-16       Impact factor: 49.962

8.  Common west African HLA antigens are associated with protection from severe malaria.

Authors:  A V Hill; C E Allsopp; D Kwiatkowski; N M Anstey; P Twumasi; P A Rowe; S Bennett; D Brewster; A J McMichael; B M Greenwood
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

9.  Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites.

Authors:  R Edelman; S L Hoffman; J R Davis; M Beier; M B Sztein; G Losonsky; D A Herrington; H A Eddy; M R Hollingdale; D M Gordon
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

10.  Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells.

Authors:  M C Seguin; F W Klotz; I Schneider; J P Weir; M Goodbary; M Slayter; J J Raney; J U Aniagolu; S J Green
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  26 in total

1.  Liver stage antigen and malaria.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-08-06       Impact factor: 4.599

Review 2.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

Review 3.  Viral vector vaccines make memory T cells against malaria.

Authors:  Arturo Reyes-Sandoval; John T Harty; Stephen M Todryk
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

4.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

5.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

6.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum.

Authors:  Collette J Hillier; Lisa A Ware; Arnoldo Barbosa; Evelina Angov; Jeffrey A Lyon; D Gray Heppner; David E Lanar
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

8.  Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.

Authors:  Henning Lauterbach; Ronny Kassub; Juliane Pätzold; Jana Körner; Michael Brückel; Admar Verschoor; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

9.  Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Authors:  H Martin Vordermeier; Shelley G Rhodes; Gillian Dean; Nilu Goonetilleke; Kris Huygen; Adrian V S Hill; R Glyn Hewinson; Sarah C Gilbert
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

10.  Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

Authors:  Chandy C John; Aaron J Tande; Ann M Moormann; Peter O Sumba; David E Lanar; Xinan M Min; James W Kazura
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.